Skip to content
Evigrade
ModerateNon-steroidal anti-inflammatory drugs (NSAIDs)×Selective serotonin reuptake inhibitors (SSRIs)

Updated · Methodology

Mechanism

Sertraline, like other selective serotonin reuptake inhibitors (SSRIs), raises the risk of bleeding, from skin haemorrhages to gastrointestinal and gynaecological bleeding, including fatal cases (sertraline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Platelets release serotonin, which is needed to stop bleeding. In epidemiological studies, a drug that interferes with serotonin reuptake taken with a non-steroidal anti-inflammatory drug (NSAID) raised the bleeding risk more than the NSAID alone (diclofenac label, US Food and Drug Administration, FDA). Diclofenac itself temporarily inhibits platelet aggregation and can cause ulcers, bleeding and perforation of the stomach or bowel. SSRIs appear in the diclofenac SmPC among the drugs that raise the risk of ulcer and gastrointestinal bleeding (diclofenac SmPC, AEMPS). Sertraline does not noticeably change diclofenac levels: it does not inhibit CYP2C9, the enzyme the liver uses to break down diclofenac, to a clinically significant degree (sertraline and diclofenac SmPCs, AEMPS).

Symptoms

Bleeding with selective serotonin reuptake inhibitors (SSRIs) ranges from bruising, haematoma, nosebleeds and petechiae to life-threatening haemorrhage (sertraline label, US Food and Drug Administration, FDA). Ulcers and bleeding in the stomach or bowel cause upper abdominal pain, indigestion, black tarry stools and vomiting blood. They can start at any time during diclofenac treatment, with or without warning symptoms (diclofenac label, FDA; diclofenac summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Hidden blood loss leads to anaemia (diclofenac label, FDA). The risk is higher in older people, in those with a past ulcer or bleed, and with higher doses and longer use of non-steroidal anti-inflammatory drugs (diclofenac SmPC, AEMPS, and label, FDA).

Management

The combination is allowed but needs caution. Under the Spanish sertraline and diclofenac summaries of product characteristics (SmPCs), special caution is needed when selective serotonin reuptake inhibitors (SSRIs) are taken with non-steroidal anti-inflammatory drugs (NSAIDs). Patients with bleeding disorders or past bleeding need even closer care (sertraline and diclofenac SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Tell the patient that the two drugs together raise the bleeding risk, and ask them to report any medicines that increase this risk, including over-the-counter ones. Monitor for signs of bleeding during treatment (sertraline and diclofenac labels, US Food and Drug Administration, FDA). Use the lowest effective diclofenac dose for the shortest possible time, start older patients on the lowest effective dose and do not add other NSAIDs (diclofenac SmPC, AEMPS). In patients taking drugs that raise the risk of gastrointestinal bleeding, SSRIs included, consider gastroprotection with misoprostol or a proton pump inhibitor (diclofenac SmPC, AEMPS). If other high-risk factors are present, such as a past ulcer or bleed, avoid NSAIDs unless the expected benefit outweighs the bleeding risk, and consider other pain relievers (diclofenac label, FDA). Stop diclofenac at once if gastrointestinal bleeding or an ulcer occurs (diclofenac SmPC, AEMPS). Diclofenac gel is barely absorbed into the blood. Under the Spanish gel SmPC, its effect on other medicines is therefore unlikely if the dose and duration of treatment are not exceeded. Under the US gel label, the same monitoring for signs of bleeding applies with SSRIs (diclofenac gel SmPC, AEMPS, and gel label, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Diclofenac

Other interactions with Sertraline